Spectrum Pharmaceuticals (SPPI) 7.20 $SPPI
Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan at the 2015 BMT Tandem Meeting
Business Wire - Thu Feb 12, 6:01AM CST
--Overall Response Rate improved from 79% at study entry to 95% after CE-Melphalan and AHCT; Complete Response Rate increased from 10 to 31%.
SPPI: 7.20 (+0.15)
Will Ligand Pharmaceuticals (LGND) Miss on Earnings in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:54AM CST
Ligand Pharmaceuticals (LGND) is scheduled to report fourth-quarter 2014 results on Feb 9, 2015 and holds a Zacks Rank #3 (Hold) with Earnings ESP of -4.17%.
ACT: 285.37 (+3.71), LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15), ARIA: 7.35 (+0.45)
Technical Scrutiny on Biotech Stocks - Galena Biopharma, Synta Pharma, Merrimack Pharma, Vertex Pharma, and Spectrum Pharma
PR Newswire - Wed Jan 07, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, January 06, 2015, the NASDAQ Composite ended at 4,592.74, down 1.29%, the Dow Jones Industrial Average edged 0.74% lower, to finish the day at 17,371.64, and the S&P 500 closed at 2,002.61, down 0.89%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 788.11, down 0.27%, while the index has advanced 6.19% in the previous three months. Register for your complimentary reports on these five stocks at:
MACK: 10.22 (+0.40), VRTX: 113.66 (+4.03), SNTA: 2.29 (-0.03), SPPI: 7.20 (+0.15), GALE: 1.68 (+0.06)
Spectrum Is An Interesting Biotechnology Investment
Value Insight - at Seeking Alpha - Tue Dec 30, 12:01PM CST
LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15)
Spectrum/Ligand Pharma Seek FDA Nod for CE-Melphalan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:00PM CST
Spectrum Pharmaceuticals (SPPI) submitted a new drug application to the FDA for Captisol-enabled melphalan (propylene glycol-free) for the multiple myeloma transplant setting.
CBST: 101.94 (+0.14), LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15), BIOD: 1.38 (-0.14)
Update: Ligand Announces Key Regulatory Submissions
Trevor Lowenthal - at Seeking Alpha - Sun Dec 28, 8:36AM CST
LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15), GSK: 47.94 (+1.99)
Spectrum Pharma submits NDA for CE-Melphalan
Seeking Alpha - at Seeking Alpha - Fri Dec 26, 11:05AM CST
LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15)
Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled(TM) Melphalan
Business Wire - Fri Dec 26, 6:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Spectrum Pharmaceuticals (NASDAQ: SPPI) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Captisol-enabled(TM) Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. Spectrum is also seeking approval for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15)
Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan
Business Wire - Fri Dec 26, 6:00AM CST
--The Company expects FDA review to take approximately 10 months.
SPPI: 7.20 (+0.15)
Spectrum Pharmaceuticals Highlights 11 Abstracts at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, December 6-9, 2014
Business Wire - Fri Dec 05, 6:00AM CST
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data related to its products at the 56th Annual Meeting of the American Society of Hematology (ASH), being held in San Francisco, California, from December 6-9, 2014.
SPPI: 7.20 (+0.15)
Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind
at The Street - Fri Nov 14, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OREX: 5.55 (+0.10), AMRN: 1.18 (unch), ICPT: 209.12 (+7.12), SPPI: 7.20 (+0.15), MNKD: 7.00 (+0.02)
Spectrum Pharmaceuticals: Update On Fusilev Generic Competition
The Visible Hand - Seeking Alpha - Wed Nov 12, 12:26PM CST
The author of this post is a private fund manager. At the time of publication, funds and accounts managed by the author were short Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ). Such funds and accounts may buy and sell securities of SPPI (and other...
SPPI: 7.20 (+0.15)
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2014 Global London Healthcare Conference on November 19th
Business Wire - Wed Nov 12, 6:00AM CST
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Jefferies 2014 Global London Healthcare Conference in London. The Company presentation is on Wednesday, November 19, 2014, at 8:40 AM GMT.
SPPI: 7.20 (+0.15)
Update: An Encouraging Third Quarter For Spectrum Pharmaceuticals
Samreen Agha - at Seeking Alpha - Mon Nov 10, 7:23AM CST
SPPI: 7.20 (+0.15)
Spectrum Pharmaceuticals' (SPPI) Raj Shrotriya CEO Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 11:56AM CST
SPPI: 7.20 (+0.15)
Spectrum Pharma posts 3Q loss
Automated Insights - Fri Nov 07, 4:04AM CST
HENDERSON, Nev. (AP) _ Spectrum Pharmaceuticals Inc. (SPPI) on Friday reported a loss of $11.5 million in its third quarter.
SPPI: 7.20 (+0.15)
Spectrum Pharmaceuticals Reports Strong Product Sales for the Third Quarter 2014; Sales of $47.9 Million up 15.6% Over Last Year
Business Wire - Thu Nov 06, 3:07PM CST
--Non-GAAP diluted EPS was $0.08, and GAAP EPS was ($0.18).
SPPI: 7.20 (+0.15)
Metastatic Uveal Melanoma Therapeutics Pipeline Review, H2 2014 - 5 Companies & 7 Drug Profiles
M2 - Thu Nov 06, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/23f5jr/metastatic_uveal) has announced the addition of the "Metastatic Uveal Melanoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Uveal Melanoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Novartis AG - Spectrum Pharmaceuticals, Inc. Drug Profiles - selumetinib sulfate - vincristine sulfate - trametinib dimethyl sulfoxide uprosertib - LY-2801653 - sotrastaurin acetate - binimetinib - emibetuzumab For more information visit http://www.researchandmarkets.com/research/23...atic_uveal
AZN: 69.96 (+0.20), SPPI: 7.20 (+0.15), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Spectrum Pharmaceuticals Announces Third Quarter 2014 Financial Results Teleconference and Webcast
Business Wire - Thu Oct 30, 6:00AM CDT
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the third quarter 2014 financial results, provide an update on the Company's business, and discuss expectations for the future.
SPPI: 7.20 (+0.15)
Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Drug Profiles from 28 Leading Pharma Companies
M2 - Thu Oct 23, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72dlvw/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - Sanofi - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Biocon Limited - Ono Pharmaceutical Co., Ltd. - Sandoz Inc. - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Takara Bio Inc. - Simcere Pharmaceutical Group - Spectrum Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - LFB S.A. - Eagle Pharmaceuticals Inc. - Areta International s.r.l. - Molecular Templates Inc. - Aprogen, Inc. - BioMedics Japan Inc. For more information visit http://www.researchandmarkets.com/research/72dlvw/bcell
IMMU: 3.84 (unch), PTLA: 34.96 (+3.13), PCYC: 163.28 (+0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SPPI: 7.20 (+0.15), BMY: 60.04 (+0.56), EGRX: 20.98 (+1.45), SGEN: 31.57 (+0.36), MRK: 58.81 (-0.07), CELGZ: 3.17 (-0.04)
Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan at the 2015 BMT Tandem Meeting
Business Wire - Thu Feb 12, 6:01AM CST
--Overall Response Rate improved from 79% at study entry to 95% after CE-Melphalan and AHCT; Complete Response Rate increased from 10 to 31%.
SPPI: 7.20 (+0.15)
Will Ligand Pharmaceuticals (LGND) Miss on Earnings in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:54AM CST
Ligand Pharmaceuticals (LGND) is scheduled to report fourth-quarter 2014 results on Feb 9, 2015 and holds a Zacks Rank #3 (Hold) with Earnings ESP of -4.17%.
ACT: 285.37 (+3.71), LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15), ARIA: 7.35 (+0.45)
Technical Scrutiny on Biotech Stocks - Galena Biopharma, Synta Pharma, Merrimack Pharma, Vertex Pharma, and Spectrum Pharma
PR Newswire - Wed Jan 07, 7:55AM CST
Investor-Edge has initiated coverage on the following equities: Galena Biopharma Inc. (NASDAQ: GALE), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, January 06, 2015, the NASDAQ Composite ended at 4,592.74, down 1.29%, the Dow Jones Industrial Average edged 0.74% lower, to finish the day at 17,371.64, and the S&P 500 closed at 2,002.61, down 0.89%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 788.11, down 0.27%, while the index has advanced 6.19% in the previous three months. Register for your complimentary reports on these five stocks at:
MACK: 10.22 (+0.40), VRTX: 113.66 (+4.03), SNTA: 2.29 (-0.03), SPPI: 7.20 (+0.15), GALE: 1.68 (+0.06)
Spectrum Is An Interesting Biotechnology Investment
Value Insight - at Seeking Alpha - Tue Dec 30, 12:01PM CST
LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15)
Spectrum/Ligand Pharma Seek FDA Nod for CE-Melphalan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 4:00PM CST
Spectrum Pharmaceuticals (SPPI) submitted a new drug application to the FDA for Captisol-enabled melphalan (propylene glycol-free) for the multiple myeloma transplant setting.
CBST: 101.94 (+0.14), LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15), BIOD: 1.38 (-0.14)
Update: Ligand Announces Key Regulatory Submissions
Trevor Lowenthal - at Seeking Alpha - Sun Dec 28, 8:36AM CST
LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15), GSK: 47.94 (+1.99)
Spectrum Pharma submits NDA for CE-Melphalan
Seeking Alpha - at Seeking Alpha - Fri Dec 26, 11:05AM CST
LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15)
Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for Captisol-Enabled(TM) Melphalan
Business Wire - Fri Dec 26, 6:30AM CST
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its partner Spectrum Pharmaceuticals (NASDAQ: SPPI) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Captisol-enabled(TM) Melphalan (CE-Melphalan) HCl for injection (propylene glycol-free) for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. Spectrum is also seeking approval for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
LGND: 55.91 (-0.35), SPPI: 7.20 (+0.15)
Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled(TM) (Propylene Glycol-Free) Melphalan
Business Wire - Fri Dec 26, 6:00AM CST
--The Company expects FDA review to take approximately 10 months.
SPPI: 7.20 (+0.15)
Spectrum Pharmaceuticals Highlights 11 Abstracts at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, December 6-9, 2014
Business Wire - Fri Dec 05, 6:00AM CST
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced key presentations of clinical and scientific data related to its products at the 56th Annual Meeting of the American Society of Hematology (ASH), being held in San Francisco, California, from December 6-9, 2014.
SPPI: 7.20 (+0.15)
Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind
at The Street - Fri Nov 14, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OREX: 5.55 (+0.10), AMRN: 1.18 (unch), ICPT: 209.12 (+7.12), SPPI: 7.20 (+0.15), MNKD: 7.00 (+0.02)
Spectrum Pharmaceuticals: Update On Fusilev Generic Competition
The Visible Hand - Seeking Alpha - Wed Nov 12, 12:26PM CST
The author of this post is a private fund manager. At the time of publication, funds and accounts managed by the author were short Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI ). Such funds and accounts may buy and sell securities of SPPI (and other...
SPPI: 7.20 (+0.15)
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2014 Global London Healthcare Conference on November 19th
Business Wire - Wed Nov 12, 6:00AM CST
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Jefferies 2014 Global London Healthcare Conference in London. The Company presentation is on Wednesday, November 19, 2014, at 8:40 AM GMT.
SPPI: 7.20 (+0.15)
Update: An Encouraging Third Quarter For Spectrum Pharmaceuticals
Samreen Agha - at Seeking Alpha - Mon Nov 10, 7:23AM CST
SPPI: 7.20 (+0.15)
Spectrum Pharmaceuticals' (SPPI) Raj Shrotriya CEO Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 11:56AM CST
SPPI: 7.20 (+0.15)
Spectrum Pharma posts 3Q loss
Automated Insights - Fri Nov 07, 4:04AM CST
HENDERSON, Nev. (AP) _ Spectrum Pharmaceuticals Inc. (SPPI) on Friday reported a loss of $11.5 million in its third quarter.
SPPI: 7.20 (+0.15)
Spectrum Pharmaceuticals Reports Strong Product Sales for the Third Quarter 2014; Sales of $47.9 Million up 15.6% Over Last Year
Business Wire - Thu Nov 06, 3:07PM CST
--Non-GAAP diluted EPS was $0.08, and GAAP EPS was ($0.18).
SPPI: 7.20 (+0.15)
Metastatic Uveal Melanoma Therapeutics Pipeline Review, H2 2014 - 5 Companies & 7 Drug Profiles
M2 - Thu Nov 06, 3:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/23f5jr/metastatic_uveal) has announced the addition of the "Metastatic Uveal Melanoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Uveal Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Uveal Melanoma and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - GlaxoSmithKline plc - Novartis AG - Spectrum Pharmaceuticals, Inc. Drug Profiles - selumetinib sulfate - vincristine sulfate - trametinib dimethyl sulfoxide uprosertib - LY-2801653 - sotrastaurin acetate - binimetinib - emibetuzumab For more information visit http://www.researchandmarkets.com/research/23...atic_uveal
AZN: 69.96 (+0.20), SPPI: 7.20 (+0.15), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Spectrum Pharmaceuticals Announces Third Quarter 2014 Financial Results Teleconference and Webcast
Business Wire - Thu Oct 30, 6:00AM CDT
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a teleconference and webcast with management to discuss the third quarter 2014 financial results, provide an update on the Company's business, and discuss expectations for the future.
SPPI: 7.20 (+0.15)
Global B-Cell Non-Hodgkin Lymphoma Therapeutics Pipeline Review H2 2014 - 43 Drug Profiles from 28 Leading Pharma Companies
M2 - Thu Oct 23, 10:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/72dlvw/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - Sanofi - Seattle Genetics, Inc. - Genentech, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Biocon Limited - Ono Pharmaceutical Co., Ltd. - Sandoz Inc. - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics, Inc. - Portola Pharmaceuticals, Inc. - Pharmacyclics, Inc. - Takara Bio Inc. - Simcere Pharmaceutical Group - Spectrum Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - LFB S.A. - Eagle Pharmaceuticals Inc. - Areta International s.r.l. - Molecular Templates Inc. - Aprogen, Inc. - BioMedics Japan Inc. For more information visit http://www.researchandmarkets.com/research/72dlvw/bcell
IMMU: 3.84 (unch), PTLA: 34.96 (+3.13), PCYC: 163.28 (+0.23), INCY: 75.94 (+0.28), AMGN: 153.48 (+0.30), SPPI: 7.20 (+0.15), BMY: 60.04 (+0.56), EGRX: 20.98 (+1.45), SGEN: 31.57 (+0.36), MRK: 58.81 (-0.07), CELGZ: 3.17 (-0.04)
